BUGWORKS is a clinical stage multi-indication therapeutics company that aims to discover novel pharmaceutical assets for combating Antimicrobial Resistance (AMR).
Bugworks is developing a novel class of antibiotics to tackle the problem of Antimicrobial Resistance (AMR).
Bugworks was founded in 2014, the company is headquartered in Bangalore, India, with offices in US and Australia.
Bugworks is developing novel therapeutic assets in the anti-infectives and immuno-oncology (IO) areas using innovative science from the frontiers of computational biology, pharmacology, structural-biology, and medicinal chemistry.
Bugworks' BWC0977 is currently in a Phase 1 clinical trial and is targeted to address unmet needs of serious hospital & community infections, and bacterial biothreats.
Bugworks' asset for IO is in the mid pre-clinical stage, targets multiple cancers and is expected to be used either standalone or in combination with immune checkpoint therapies.
Bugworks is backed by Lightrock India, University of Tokyo Edge Capital (UTEC), Global Brain Corporation (Global Brain) Japan, Acquipharma Holdings, 3ONE4Capital India, S.A, I.M Holdings, and others. The company raised $18M in Series B-1 round on Feb 09, 2022. This brings Bugworks' total funding to $34.5M to date.